Wang Jia, Yang Lu, Du Shigang, Pan Yi, Zhao Ling, Li Haihao, Zhou Zeping, Ke Tingyu
The Second Clinical Medical College, Kunming Medical University, Kunming, China.
Department of Endocrinology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China.
Eur J Med Res. 2025 Mar 28;30(1):211. doi: 10.1186/s40001-025-02497-4.
Given the role of thyroid hormones (THs) in metabolism, growth and development, their involvement in carcinogenesis and cancer progression in the context of bladder cancer (BC) warrants further investigation. This study aimed to investigate the associations between TH levels and the incidence and stage of BC.
A cohort of 46 diagnosed BC patients with no history of thyroid disease, and 47 healthy controls were analysed. BC patients were classified into NMIBC and MIBC according to the 2017 TNM staging system (AJCC, 8th edition). Thyroid hormones and antibodies were measured. Statistical analysis was performed via SPSS software to evaluate differences in thyroid parameters between BC patients and healthy controls, and between non-muscle invasive bladder cancer (NMIBC) patients and muscle invasive bladder cancer (MIBC) patients.
Compared with healthy controls, BC patients had higher levels of thyrotropin (TSH), total triiodothyronine (TT3), total thyroxine (TT4) and thyroglobulin and lower levels of thyroid peroxidase antibody (TPOAb). Compared with controls, both NMIBC patients and MIBC patients had elevated TT3 and TT4 levels. The proportions of NMIBC and MIBC patients were significantly greater in the high TSH, TT3, and TT4 groups than in the low TSH, TT3 and TT4 groups.
Elevated levels of TSH, TT3 and TT4 and low levels of TPOAb within the normal range appear to be associated with increased incidence and stage of BC. These findings suggest that TSH, TT3, TT4 and TPOAb levels may be useful for assessing BC prognosis and may provide new insights into therapeutic strategies.
鉴于甲状腺激素（THs）在代谢、生长和发育中的作用，其在膀胱癌（BC）发生和癌症进展中的作用值得进一步研究。本研究旨在探讨甲状腺激素水平与膀胱癌发病率及分期之间的关联。
分析了一组46例无甲状腺疾病史的确诊膀胱癌患者和47例健康对照。根据2017年TNM分期系统（美国癌症联合委员会第8版）将膀胱癌患者分为非肌层浸润性膀胱癌（NMIBC）和肌层浸润性膀胱癌（MIBC）。检测甲状腺激素和抗体。通过SPSS软件进行统计分析，以评估膀胱癌患者与健康对照之间，以及非肌层浸润性膀胱癌（NMIBC）患者与肌层浸润性膀胱癌（MIBC）患者之间甲状腺参数的差异。
与健康对照相比，膀胱癌患者促甲状腺激素（TSH）、总三碘甲状腺原氨酸（TT3）、总甲状腺素（TT4）和甲状腺球蛋白水平较高，甲状腺过氧化物酶抗体（TPOAb）水平较低。与对照相比，NMIBC患者和MIBC患者的TT3和TT4水平均升高。高TSH、TT3和TT4组中NMIBC和MIBC患者的比例显著高于低TSH、TT3和TT4组。
正常范围内TSH、TT3和TT4水平升高以及TPOAb水平降低似乎与膀胱癌发病率和分期增加有关。这些发现表明，TSH、TT3、TT4和TPOAb水平可能有助于评估膀胱癌预后，并可能为治疗策略提供新的见解。
